Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
Metabolic disease specialist Poxel looked set to close Friday’s trading up more than 9%. 20 December 2019
Biotechnology
In a second licensing deal signed by the Japanese pharma major this week, Takeda Pharmaceuticals has entered into a billion-dollar deal with privately-held Canadian biotech Turnstone Biologics to develop multiple products from its proprietary vaccinia virus platform targeting a broad range of cancer indications. 20 December 2019
Biotechnology
Thriving Danish biotech company Genma has entered a deal with CureVac, a privately-held messenger RNA (mRNA) company. 20 December 2019
Biotechnology
Announcing its first commercial deal, US biotech start-up Rheos Medicines yesterday said that it has entered into a worldwide exclusive collaboration, option and license agreement with Swiss pharma giant Roche to discover, develop and commercialize novel therapeutics in the field of immunometabolism. 20 December 2019
Biotechnology
US RNA-targeted drug developer Ionis Pharmaceuticals yesterday revealed that Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production of microtubule-associated protein tau (MAPT), or tau, in the central nervous system. 20 December 2019
Biotechnology
Oslo-based biotech Zelluna Immunotherapy has appointed Namir Hassan as chief executive officer, replacing Miguel Forte. 19 December 2019
Biotechnology
A more personalized series of options are emerging to treat human epidermal growth factor receptor 2 negative (HER2) hormone receptor positive (HR+) breast cancer, according to GlobalData. 19 December 2019
Biotechnology
Oxford Biomedica today announced an extension to its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Swiss pharma giant’s CAR-T portfolio including five lentiviral vectors for CAR-T products 19 December 2019
Biotechnology
East Coast, USA-based cancer specialist Epizyme has scored a unanimous vote in favor of its candidate tazemetostat, from the US regulator's cancer advisory panel. 19 December 2019
Biotechnology
Minerva Neurosciences yesterday announced disappointing Phase IIb trial of MIN-117 in adult patients suffering from moderate to severe major depressive disorder (MDD) and presenting with symptoms of anxious distress failed to meet its primary and key secondary endpoints. 19 December 2019
Biotechnology
The US Food and Drug Administration has accepted US pharm giant Pfizer’s supplemental New Drug Application (sNDA) for Braftovi (encorafenib), in combination with Erbitux (cetuximab; Braftovi Doublet) based on the results from the Phase III BEACON CRC trial. 19 December 2019
Biotechnology
European Commission has granted approval for Rinvoq (upadacitinib) for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). 19 December 2019
Biotechnology
The US Food and Drug Administration’s (FDA) Janet Woodcock has delivered a statement on the impact of the agency’s proposals on bringing low-cost biosimilar and interchangeable protein products to market. 18 December 2019
Biotechnology
Keytruda (pembrolizumab) looks set to become the first in its class to win approval for a hard-to-treat kind of bladder cancer, following a positive vote from the US regulator’s cancer advisory panel. 18 December 2019
Biotechnology
Californian company Adamas Pharmaceuticals closed 43% down after Tuesday’s trading, despite the firm announcing that a Phase III trial had met its primary endpoint. 18 December 2019
Biotechnology
Cerevance, a UK-based clinical-stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance with Japan’s Takeda Pharmaceutical to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain gastrointestinal (GI) disorders. 18 December 2019
Biotechnology
In a surprise move, Ipsen chief executive David Meek has quit his position at the French drugmaker to take the helm at a small gene therapy startup, FerGene. 18 December 2019
Biotechnology
The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) voted by a narrow margin of 7 to 5 in favor of recommending Lynparza (olaparib) as a first-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas, whose disease has not progressed following 1st-line platinum-based chemotherapy 18 December 2019
Biotechnology
US biotech Alnylam Pharmaceuticals cemented its standing as the leading RNAi therapeutics company on Tuesday by presenting positive Phase III data on its latest candidate. 17 December 2019
Biotechnology
USA-based genetics medicines developer Wave Life Sciences saw its shares crash more than 55% to $26.79 by close of trading Monday, after announcing the discontinuation of two trials in Duchenne muscular dystrophy (DMD). 17 December 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze